Voltammetric analysis for distinguishing portal hypertension-related from malignancy-related ascites: A proof of concept study.
Aged
Aged, 80 and over
Albumins
/ analysis
Ascites
/ diagnosis
Ascitic Fluid
/ chemistry
Biomarkers
/ analysis
Chemistry Techniques, Analytical
/ methods
Diagnosis, Differential
Electrochemical Techniques
/ methods
Female
Humans
Hypertension, Portal
/ complications
Male
Middle Aged
Neoplasms
/ complications
Pattern Recognition, Automated
Proof of Concept Study
Serum Albumin, Human
/ analysis
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
04
2020
accepted:
04
05
2020
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
25
8
2020
Statut:
epublish
Résumé
Serum-ascites albumin gradient (SAAG) remains the most sensitive and specific marker for the differentiation of ascites due to portal hypertension from ascites due to other causes. SAAG has some limitations and may fail in selected conditions. Voltammetric analysis (VA) has been used for the detection of electroactive species of biological significance and has proven effective for detection infections in biological fluids. In this study, we compared the accuracy of voltammetric analysis (VA) with that of SAAG to differentiate ascites due to portal hypertension from that having a different origin. 80 ascites samples were obtained from patients undergoing paracentesis at the Campus Bio-Medico Hospital of Rome. VA was performed using the BIONOTE device. The ability of VA to discriminate ascitic fluid etiology and biochemical parameters was evaluated using Partial Least Square Discriminant Analysis (PLS-DA), with ten-fold cross-validations. Mean age was 68.6 years (SD 12.5), 58% were male. Ascites was secondary to only portal hypertension in 72.5% of cases (58 subjects) and it was secondary to a baseline neoplastic disease in 27.5% of cases (22 subjects). Compared to SAAG≥1.1, e-tongue predicted ascites from portal hypertension with a better accuracy (92.5% Vs 87.5%); sensitivity (98.3% Vs 94.8%); specificity (77.3% Vs 68.2%); predictive values (PPV 91.9% Vs 88.7% and NPV 94.4% Vs 83.3%). VA correctly classified ascites etiology in 57/58 (98.2%) of cases with portal hypertension and in 17/22 (77.2%) of cases with malignancy. Instead, VA showed poor predictive capacities towards total white blood count and polymorphonuclear cell count. According to this proof of concept study, VA qualifies as a promising low-cost and easy method to discriminate between ascites secondary to portal hypertension and ascites due to malignancy.
Sections du résumé
BACKGROUND
Serum-ascites albumin gradient (SAAG) remains the most sensitive and specific marker for the differentiation of ascites due to portal hypertension from ascites due to other causes. SAAG has some limitations and may fail in selected conditions. Voltammetric analysis (VA) has been used for the detection of electroactive species of biological significance and has proven effective for detection infections in biological fluids.
AIMS
In this study, we compared the accuracy of voltammetric analysis (VA) with that of SAAG to differentiate ascites due to portal hypertension from that having a different origin.
METHODS
80 ascites samples were obtained from patients undergoing paracentesis at the Campus Bio-Medico Hospital of Rome. VA was performed using the BIONOTE device. The ability of VA to discriminate ascitic fluid etiology and biochemical parameters was evaluated using Partial Least Square Discriminant Analysis (PLS-DA), with ten-fold cross-validations.
RESULTS
Mean age was 68.6 years (SD 12.5), 58% were male. Ascites was secondary to only portal hypertension in 72.5% of cases (58 subjects) and it was secondary to a baseline neoplastic disease in 27.5% of cases (22 subjects). Compared to SAAG≥1.1, e-tongue predicted ascites from portal hypertension with a better accuracy (92.5% Vs 87.5%); sensitivity (98.3% Vs 94.8%); specificity (77.3% Vs 68.2%); predictive values (PPV 91.9% Vs 88.7% and NPV 94.4% Vs 83.3%). VA correctly classified ascites etiology in 57/58 (98.2%) of cases with portal hypertension and in 17/22 (77.2%) of cases with malignancy. Instead, VA showed poor predictive capacities towards total white blood count and polymorphonuclear cell count.
CONCLUSIONS
According to this proof of concept study, VA qualifies as a promising low-cost and easy method to discriminate between ascites secondary to portal hypertension and ascites due to malignancy.
Identifiants
pubmed: 32437441
doi: 10.1371/journal.pone.0233350
pii: PONE-D-20-09873
pmc: PMC7241828
doi:
Substances chimiques
Albumins
0
Biomarkers
0
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0233350Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Pharm Biomed Anal. 2001 Dec;26(5-6):1009-15
pubmed: 11600314
J Hepatol. 2000 Jan;32(1):142-53
pubmed: 10673079
Biosens Bioelectron. 2008 Jan 18;23(6):795-802
pubmed: 17931852
Sci Rep. 2017 Sep 20;7(1):11938
pubmed: 28931931
Hepatology. 1992 Aug;16(2):396-403
pubmed: 1639349
Am J Clin Pathol. 1976 Jul;66(1):91-5
pubmed: 937276
BMC Gastroenterol. 2016 Oct 13;16(1):132
pubmed: 27733127
World J Gastroenterol. 2019 Aug 14;25(30):4043-4050
pubmed: 31435162
Liver Int. 2017 Feb;37(2):242-250
pubmed: 27496750
Gastroenterology. 1983 Aug;85(2):240-4
pubmed: 6862152
Ann Clin Biochem. 2010 Sep;47(Pt 5):397-407
pubmed: 20595402
Sci Rep. 2016 May 05;6:25337
pubmed: 27145718
J Transl Med. 2018 Jan 25;16(1):17
pubmed: 29370807
Ann Surg. 1980 Dec;192(6):738-42
pubmed: 7447527
Ann Oncol. 2007 May;18(5):945-9
pubmed: 17298959
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):396-400
pubmed: 7948823
Hepatology. 2007 May;45(5):1275-81
pubmed: 17464969
Front Chem. 2018 Aug 10;6:327
pubmed: 30148129
Ann Hepatol. 2014 May-Jun;13(3):357-63
pubmed: 24756011
Wound Repair Regen. 2019 May;27(3):288-291
pubmed: 30663822
Talanta. 2009 Jan 15;77(3):1097-104
pubmed: 19064097
J Hepatol. 2010 Sep;53(3):397-417
pubmed: 20633946
Sensors (Basel). 2013 Dec 04;13(12):16625-40
pubmed: 24304640
Ann Intern Med. 1992 Aug 1;117(3):215-20
pubmed: 1616215
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
Hepatology. 2003 Apr;37(4):893-6
pubmed: 12668983
J Physiol. 1896 May 5;19(4):312-26
pubmed: 16992325
Hepatology. 2009 Jun;49(6):2087-107
pubmed: 19475696
Clin Chim Acta. 2004 May;343(1-2):61-84
pubmed: 15115678